World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00317538
Date of registration: 21/04/2006
Prospective Registration: No
Primary sponsor: Centocor Ortho Biotech Services, L.L.C.
Public title: Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept
Scientific title: Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept
Date of first enrolment: June 2003
Target sample size: 28
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00317538
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 3
Countries of recruitment
Contacts
Name:     Centocor Ortho Biotech Services, L.L.C. Clinical Trial
Address: 
Telephone:
Email:
Affiliation:  Centocor Ortho Biotech Services, L.L.C.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients have a diagnosis of RA according to the revised 1987 criteria of the
American Rheumatism Association

- Have been receiving background MTX for at least 2 months prior to week -4

- Have been receiving a stable etanercept dose of 25 mg subcutaneously twice weekly for
at least 2 months prior to week -4

- Must have been using oral or parenteral MTX for the 2 months prior to screening and
at a stable dose of 7.5 to 25 mg per week between week -4 and week 0

- Have shown improvement in signs and symptoms of RA in response to etanercept and MTX
according to both the patient and the treating physician

- Have active disease as defined by both a TJC of at least 9 (on the 68 joint set) and
SJC of at least 6 (on the 66 joint set)

- Have a documented negative reaction to a purified protein derivative (PPD) skin test
(PPD induration< 5 mm) performed within 3 months prior to the week 0 visit

Exclusion Criteria:

- Patients have been receiving corticosteroids (ie, via any route) at doses > 10 mg
prednisone equivalent daily or have not been taking a stable dose of corticosteroids
for at least 1 month prior to week -4

- Have started receiving nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 month
of week -4 or have not been on a stable dose of NSAIDs for at least 1 month prior to
week -4

- Have received disease modifying anti-rheumatic drugs (DMARDs) or immunosuppressives
(except MTX) for at least 1 month prior to week 0

Patients who have received any prior treatment with infliximab or with any other
therapeutic agent targeted at reducing TNF, except etanercept, (e.g.pentoxifylline or
thalidomide)

- Patients with a concomitant diagnosis of Congestive Heart Failure, including
medically controlled asymptomatic patients

- Any current known malignancy or history of malignancy within the previous 5 years

- Serious infection within the past 3 months or history of chronic infection such as
hepatitis, pneumonia, or pyelonephritis in the previous 3 months, any opportunistic
infections

- known substance abuse (drug or alcohol) within the previous 3 years

- Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or
within the 6-month period thereafter.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Drug: infliximab, etanercept
Primary Outcome(s)
Evaluate safety and evidence of therapeutic benefit of infliximab and methotrexate, in patients with rheumatoid arthritis who have had an incomplete response to etanercept and methotrexate (MTX), at week 16
Secondary Outcome(s)
Evaluate pharmacokinetics, immunogenicity, structural damage and pharmacodynamics over the study period
Secondary ID(s)
CR003136
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history